Search
Telomir Pharmaceuticals Inc
TELOAdd to Watchlist
1.110USD
+0.020+1.83%
Market hours （ET）Quotes delayed by 15 min
76.34MMarket Cap
LossP/E TTM
More Details of Telomir Pharmaceuticals Inc Company
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Telomir Pharmaceuticals Inc Profile
Ticker SymbolTELO
Company nameTelomir Pharmaceuticals Inc
IPO dateFeb 09, 2024
CEOAminov (Erez)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 09
Address900 West Platt Street, Suite 200
CityTAMPA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33606
Phone18138642562
Websitehttps://telomirpharma.com/
Ticker SymbolTELO
IPO dateFeb 09, 2024
CEOAminov (Erez)
Company Executives of Telomir Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
,
,
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
7.75M
-12.65%
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Telomir Pharmaceuticals Inc?
The top five shareholders of Telomir Pharmaceuticals Inc are: Mr. Erez Aminov
How many institutions hold shares of Telomir Pharmaceuticals Inc (TELO)?
As of 2026Q1, 110 institutions hold shares of Telomir Pharmaceuticals Inc, with a combined market value of approximately 3.42M, accounting for 9.95% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 488600.00.